Quick Summary
- Record Revenue: Reached $58.74 billion in FY 2025, an 8% increase at constant exchange rates (CER).
- Profit Growth: Core Earnings Per Share (EPS) rose 11% to $9.16, outperforming revenue growth.
- Blockbuster Portfolio: Expanded to 16 medicines generating over $1 billion in annual sales.
- Clinical Momentum: Achieved 16 positive Phase III readouts and 43 major approvals globally in 2025.
- Dividends: Total dividend increased to $3.20 per share (a 3% year-over-year rise).
- 2026 Guidance: Forecasts mid-to-high single-digit revenue growth and low double-digit Core EPS growth.
- Strategic Listing: Successfully transitioned to the New York Stock Exchange (NYSE) on February 2, 2026.
- Ambition 2030: Reaffirmed long-term target of reaching $80 billion in revenue by 2030.
AstraZeneca (LSE/STO/Nasdaq: AZN) today reported a powerhouse performance for the 2025 fiscal year, driven by double-digit earnings growth and a rapidly diversifying pipeline. The pharmaceutical giant saw its Total Revenue climb to $58.74 billion, an 8% increase at constant exchange rates (CER), fueled by strong demand across its core oncology, cardiovascular, and rare disease portfolios.
The company now boasts 16 blockbuster medicines generating over $1 billion in annual sales, marking a major milestone in CEO Pascal Soriot’s “Ambition 2030” strategy to reach $80 billion in revenue by the end of the decade.
Financial Highlights: Growth Across the Board
AstraZeneca’s 2025 results reflected broad-based commercial success. Key financial metrics included:
- Core Earnings Per Share (EPS): Rose 11% (CER) to $9.16, slightly ahead of analyst expectations.
- Total Revenue: Reached $58,739 million, up 9% at actual exchange rates.
- Dividend Increase: The Board declared a second interim dividend of $2.17, bringing the total dividend for the year to $3.20, a 3% increase over 2024.
- Operating Profit: Core Operating Profit increased by 9% (CER) to $18.5 billion, maintaining a healthy core operating margin of 31%.
Therapy Area Performance: Oncology and CVRM Lead
Oncology remains the company’s largest engine, representing 44% of total product revenue.
- Oncology: Sales grew significantly, supported by the continued global expansion of Tagrisso, Imfinzi, and the HER2-directed antibody-drug conjugate Enhertu.
- CVRM (Cardiovascular, Renal & Metabolism): Contributed 22% of revenue, driven by the blockbuster performance of Farxiga, which continues to see high demand for heart failure and chronic kidney disease indications.
- Rare Disease: Following the Alexion acquisition, this segment now accounts for 16% of revenue, providing a stable, high-margin foundation for the group.
Read More: AstraZeneca Announces $50 Billion Investment in the United States
A “Catalyst-Rich” Pipeline
CEO Pascal Soriot described 2025 as a year of “excellent pipeline delivery.” The company achieved 16 positive Phase III readouts and secured 43 major regulatory approvals in key markets over the last 12 months.
The momentum across our company is continuing into 2026,” Soriot stated. “We are looking forward to the results of more than 20 Phase III trial readouts this year. We have more than 100 Phase III studies ongoing, including transformative technologies that have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030.
Pascal Soriot
The company is particularly focused on its next-generation Antibody-Drug Conjugates (ADCs) and bispecifics, with 8 wholly-owned ADCs currently in clinical trials.
Strategic Milestone: NYSE Harmonization
AstraZeneca also highlighted a structural change to its listing. As of February 2, 2026, the company’s ordinary shares began trading on the New York Stock Exchange (NYSE), harmonizing its listing structure across London, New York, and Stockholm. This move is intended to improve liquidity and allow a broader range of global investors to participate in the company’s growth.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
2026 Guidance: Sustained Momentum
AstraZeneca issued a confident outlook for 2026, despite anticipated headwinds such as China’s Volume-Based Procurement (VBP) impacting Farxiga and Lynparza, and the U.S. loss of exclusivity for Farxiga in April 2026.
- Revenue Guidance: Mid-to-high single-digit percentage increase.
- Core EPS Guidance: Low double-digit percentage increase.
- Capital Expenditure: Expected to rise by roughly one-third in 2026 to support multi-year manufacturing and R&D projects.
Last Modified:
